VE-822: Selective ATR Inhibitor for Cancer Radiosensitization

Executive Summary: VE-822 (APExBIO, SKU B1383) is a highly selective ATR kinase inhibitor with an IC₅₀ of 0.019 μM, enabling precise disruption of the DNA damage response in cancer cells (APExBIO product page). It increases radiosensitivity and chemosensitivity, particularly in pancreatic ductal adenocarcinoma (PDAC) cells with p53 or K-Ras mutations (Parra et al., 2025). VE-822 acts by blocking ATR-mediated checkpoint signaling, thereby reducing homologous recombination repair and enhancing persistent DNA damage under genotoxic stress. In vivo, oral administration of VE-822 at 60 mg/kg in combination with radiation or gemcitabine significantly delays tumor growth without exacerbating normal tissue toxicity. The compound’s solubility profile and storage stability make it well-suited for preclinical research into radiosensitization strategies.

Biological Rationale

ATR (ataxia telangiectasia and Rad3-related) kinase is a master regulator of the DNA damage response (DDR), particularly in response to replication stress and DNA double-strand breaks. Cancer cells, especially those with defects in TP53 or K-Ras, exhibit high replication stress and are reliant on ATR-mediated signaling for survival during genotoxic insult. Inhibiting ATR kinase disrupts cell cycle checkpoints (notably the G2/M checkpoint), impairs DNA repair by homologous recombination, and results in accumulation of unrepaired DNA damage, selectively sensitizing tumor cells to radiation and chemotherapy (Parra et al., 2025).

VE-822 is a close analog of VE-821, designed to improve potency and selectivity for ATR. Its role as a radiosensitizer is particularly relevant for tumors with intrinsic or acquired radioresistance, such as PDAC (see this review). This article extends previous discussions by providing a detailed account of VE-822’s preclinical benchmarks and workflow parameters for translational research.

Mechanism of Action of VE-822

VE-822 binds to the catalytic domain of ATR kinase, competitively inhibiting its activity at nanomolar concentrations (IC₅₀ = 0.019 μM in biochemical assays, DMSO, room temperature) [APExBIO]. By blocking ATR, VE-822 prevents phosphorylation of key downstream effectors such as Chk1 at Ser345. This abrogates the activation of S and G2/M checkpoints following DNA damage or replication stress, leading to premature mitotic entry and mitotic catastrophe in cancer cells (see mechanistic insight). The inhibitor also reduces homologous recombination repair efficiency, evidenced by decreased RAD51 foci formation after irradiation.

VE-822’s selectivity profile ensures minimal off-target inhibition of related kinases such as ATM or DNA-PKcs at effective concentrations [APExBIO]. This selectivity allows for preferential sensitization of tumor cells over normal cells, especially under conditions of combined DNA damaging therapies.

Evidence & Benchmarks

• VE-822 demonstrates potent ATR inhibition with biochemical IC₅₀ of 0.019 μM under standard assay conditions (DMSO, 25°C) (APExBIO).
• In PDAC xenograft mouse models, daily oral VE-822 (60 mg/kg) plus radiation and gemcitabine significantly increases tumor growth delay without added normal tissue toxicity (Parra et al., 2025).
• VE-822 reduces homologous recombination, as measured by RAD51 foci, and increases persistent γH2AX foci in irradiated cancer cells (GemcitabineHCl review).
• In 2D and 3D cancer spheroid models, ATR inhibition by VE-822 or its clinical analog (M6620) yields DEF_0.1SF > 1.4 at relevant concentrations, indicating strong radiosensitization (Parra et al., 2025).
• VE-822 is soluble at ≥50 mg/mL in DMSO but insoluble in water or ethanol; warming and ultrasonic treatment can improve dissolution (per APExBIO guidelines).

Applications, Limits & Misconceptions

VE-822 is widely used in preclinical research for:

• Sensitizing PDAC and other solid tumors to radiation and chemotherapeutics, especially in TP53 or K-Ras mutant contexts.
• Studying ATR-dependent cell cycle checkpoint regulation and homologous recombination repair.
• Developing radiosensitization strategies for translational oncology workflows.
• Integrating with iPSC-based and 3D culture screening platforms to model clinically relevant tumor microenvironments (see iPSC-based platform review).

Unlike broad-spectrum DDR inhibitors, VE-822’s selectivity reduces off-target effects in normal tissue, supporting its utility in preclinical combination regimens (see strategic guidance). This article further updates previous guidance by delineating practical limits for workflow optimization.

Common Pitfalls or Misconceptions

• VE-822 does not significantly sensitize normal (non-tumor) cells to radiation at effective concentrations; effects are tumor-selective (Parra et al., 2025).
• Not effective as a single agent in tumor models lacking replication stress or DDR defects.
• Solubility issues: VE-822 is insoluble in water/ethanol and requires DMSO; improper dissolution can yield inconsistent results.
• Stock solutions are stable at -20°C for short-term use; long-term storage or freeze-thaw cycles may reduce potency (APExBIO).
• VE-822 does not inhibit ATM or DNA-PKcs at relevant concentrations; off-target DDR effects are minimal.

Workflow Integration & Parameters

VE-822 (B1383, APExBIO) is supplied as a lyophilized powder or DMSO stock. For in vitro use, dissolve at ≥50 mg/mL in DMSO; use ultrasonic bath and gentle warming if needed. For in vivo studies, VE-822 is typically administered via oral gavage at 60 mg/kg/day, dissolved in DMSO and further diluted in vehicle (e.g., 0.5% methylcellulose) immediately before dosing [APExBIO]. Store stock at -20°C and avoid repeated freeze-thaw cycles.

Experimental workflows commonly combine VE-822 with DNA-damaging agents (e.g., radiation, gemcitabine) in 2D and 3D culture assays. Quantify radiosensitization using colony formation, γH2AX or RAD51 foci, and survival fraction endpoints. For optimal results, match dosing and timing to the cell line’s cell cycle phase and DNA repair status.

Conclusion & Outlook

VE-822 is an enabling technology for DDR pathway interrogation and radiosensitization research in oncology. Its high selectivity and potency make it ideal for modeling ATR-dependent repair and checkpoint mechanisms, especially in PDAC and other solid tumors with high replication stress. The compound’s suitability for advanced workflows, including iPSC-derived models and 3D spheroid assays, positions it at the forefront of translational cancer research. For further details, see the VE-822 product page (APExBIO).

This article extends previous coverage by providing atomic, experimentally grounded benchmarks and workflow parameters, supporting rigorous and reproducible translational research with VE-822.